News Releases

Product-related press releases will be removed from our website within three weeks after publication. Press releases are made available for the media and to comply with applicable rules and regulations they are removed from our website. Previous press releases can be provided upon request. Please contact us here.

April 3, 2023
Ascendis Pharma Provides Update on Regulatory Reviews of TransCon PTH™ in Hypoparathyroidism
February 16, 2023
Ascendis Pharma Reports Full Year 2022 Results
January 8, 2023
Ascendis Pharma Provides Update on Vision 3x3 Strategic Roadmap at 41st Annual J.P. Morgan Healthcare Conference
January 4, 2023
Online Enrollment Now Open for Physicians Requesting Expanded Access to Ascendis Pharma’s TransCon™ PTH for Eligible U.S. Adult Patients with Hypoparathyroidism
Displaying 21 - 27 of 27